IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Korea Investment CORP

Korea Investment CORP grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,917 shares of the company's stock after purchasing an additional 880 shares during the period. Korea Investment CORP owned approximately 0.07% of IDEXX Laboratories worth $25,186,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of IDXX. Cranbrook Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares during the period. Summit Trail Advisors LLC grew its stake in IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares in the last quarter. IFP Advisors Inc increased its holdings in IDEXX Laboratories by 3.6% during the 4th quarter. IFP Advisors Inc now owns 903 shares of the company's stock worth $373,000 after purchasing an additional 31 shares during the period. Finally, Cape Cod Five Cents Savings Bank raised its position in IDEXX Laboratories by 0.5% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company's stock valued at $3,091,000 after purchasing an additional 32 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several research firms have commented on IDXX. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Trading Up 0.8 %

Shares of NASDAQ IDXX traded up $3.26 on Wednesday, reaching $421.83. 142,217 shares of the company traded hands, compared to its average volume of 582,433. The company has a 50 day moving average of $436.90 and a 200 day moving average of $441.45. The stock has a market capitalization of $34.19 billion, a PE ratio of 39.63, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.